Halozyme Therapeutics Inc (HALO) — Upcoming Catalysts

FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for Halozyme Therapeutics Inc, built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.

For informational purposes only — not investment advice. Track HALO live on Mooboard →

Later1

  • Mar 2028
    Halozyme Therapeutics Inc(HALO)Phase 2/3 readout
    Testosterone enanthate · Phase 3 · Hypogonadism, Male
    NCT06689085: 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism. Primary completion 2028-03 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗

How Halozyme Therapeutics Inc has moved — past-year price reactions

How binary is HALO? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.

1.2%
typical day (1Y)
1
±10% days
36.8%
annualized vol
250
trading days
Largest single-day moves
  • +20.2%2026-08-073 HALO Stocks to Buy Now · The Globe and Mail
  • -9%2026-02-18no matched headline
  • +6.8%2026-05-12no matched headline
  • +5.3%2026-06-03no matched headline
  • +5.2%2025-11-24no matched headline
  • -4.6%2025-12-01no matched headline

Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.

See the full biopharma catalyst calendar across all covered companies.